HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arylessence offers new take on rose fragrance

This article was originally published in The Rose Sheet

Executive Summary

Acknowledging that rose fragrances are making a comeback, Arylessence introduces new collection "based on inspiring, true-to-the-rose accords [that] combine surprising fruit, spice and sweet notes to create original perfumes that consumers have never experienced before," according to June 8 release. "These new rose fragrances aren't your grandmother's rose," says Chief Perfumer Bruce Garlick. Firm's Black Rose features "deep blackberry notes to add depth and dimension" and Lychee Rose contains moisture of the ancient Chinese fruit to "enhance the dewy nature of rose." Range also includes Peppercorn Rose and Rose Honey. "Different from traditional, cloying rose scents, they will transform the way consumers think about rose fragrances," the fragrance and flavor manufacturer says

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel